Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pneumococcal Disease
Reports from J.G. Schenkein et al highlight recent research in pneumococcal disease
May 7th, 2008
According to recent research from the United States, "Despite a level ''A'' recommendation by the Centers for Disease Control and Prevention, the use of pneumococcal polysaccharide vaccination in patients with COPD is supported by limited data. Clinical and laboratory studies have suggested that the currently approved vaccine is less effective in the population of COPD patients than in healthier patients, and to date no randomized-controlled trial of pneumococcal vaccination for COPD patients has demonstrated any beneficial effect." "The implementation of a pneumococcal vaccine trial in the COPD population is problematic because of the large sample size required for...
Source: Vaccine Weekly (2008-05-07)
|
